GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Oncotherapy PLC (FRA:R3I1) » Definitions » Equity-to-Asset

Advanced Oncotherapy (FRA:R3I1) Equity-to-Asset : 0.40 (As of Jun. 2022)


View and export this data going back to 2018. Start your Free Trial

What is Advanced Oncotherapy Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Advanced Oncotherapy's Total Stockholders Equity for the quarter that ended in Jun. 2022 was €70.51 Mil. Advanced Oncotherapy's Total Assets for the quarter that ended in Jun. 2022 was €178.45 Mil.

The historical rank and industry rank for Advanced Oncotherapy's Equity-to-Asset or its related term are showing as below:

FRA:R3I1's Equity-to-Asset is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.64
* Ranked among companies with meaningful Equity-to-Asset only.

Advanced Oncotherapy Equity-to-Asset Historical Data

The historical data trend for Advanced Oncotherapy's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Oncotherapy Equity-to-Asset Chart

Advanced Oncotherapy Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.63 0.57 0.39 0.36 0.43

Advanced Oncotherapy Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.36 0.29 0.43 0.40

Competitive Comparison of Advanced Oncotherapy's Equity-to-Asset

For the Medical Devices subindustry, Advanced Oncotherapy's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Oncotherapy's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced Oncotherapy's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Advanced Oncotherapy's Equity-to-Asset falls into.



Advanced Oncotherapy Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Advanced Oncotherapy's Equity to Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Equity to Asset (A: Dec. 2021 )=Total Stockholders Equity/Total Assets
=72.223/166.28
=

Advanced Oncotherapy's Equity to Asset Ratio for the quarter that ended in Jun. 2022 is calculated as

Equity to Asset (Q: Jun. 2022 )=Total Stockholders Equity/Total Assets
=70.51/178.45
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advanced Oncotherapy  (FRA:R3I1) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Advanced Oncotherapy Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Advanced Oncotherapy's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Oncotherapy (FRA:R3I1) Business Description

Traded in Other Exchanges
N/A
Address
4 Tenterden Street, Third Floor, London, GBR, W1S 1TE
Advanced Oncotherapy PLC is active in the healthcare domain in the United Kingdom. As a medical care provider, its focus is to develop technologies to maximize the destructive effect of radiation on tumors whilst minimizing damage to healthy tissues. It develops an affordable proton-based radiotherapy system, using innovative and clinically effective technology, thereby contributing to curing critical unmet conditions. The company's only business segment is Proton Therapy.

Advanced Oncotherapy (FRA:R3I1) Headlines

No Headlines